Angiotensin-Converting Enzyme Inhibitors

DRUG4 trials

Sponsors

National Heart, Lung, and Blood Institute (NHLBI), Nara Medical University, Baylor Research Institute, Boehringer Ingelheim

Conditions

Brain InfarctionCardiovascular DiseasesCoronary DiseaseHeart DiseasesHypertensionMyocardial InfarctionMyocardial Ischemia

Phase 3

Prevention of Events With Angiotensin-Converting Enzyme Inhibitor Therapy (PEACE)

CompletedNCT00000558

National Heart, Lung, and Blood Institute (NHLBI)Cardiovascular Diseases, Coronary Disease, Heart Diseases +2

Start: 1995-11-30End: 2005-06-30Updated: 2016-04-15

Phase 4

Angiotensin II Receptor Blockers (ARB) and ACE Inhibitors (ACEI) on Silent Brain Infarction and Cognitive Decline

CompletedNCT00126516

Nara Medical UniversityBrain Infarction, Hypertension

Start: 2004-05-31End: 2013-06-30Updated: 2013-10-30

Unknown Phase

Impact of Medical and Surgical Therapy on Functional Mitral Regurgitation

CompletedNCT00224809

Baylor Research InstituteCardiovascular Diseases, Coronary Disease, Heart Diseases

Start: 2002-09-30End: 2007-05-31Target: 250Updated: 2014-02-19

Effect of Caldine® on Renal Function in Balanced Hypertension

TerminatedNCT02240641

Boehringer IngelheimHypertension

Start: 1998-05-31Updated: 2014-09-16

Related Papers

Plasma osteoprotegerin predicts adverse cardiovascular events in stable coronary artery disease: the PEACE trial

Frontiers in Cardiovascular Medicine2023-06-149 citations

Abstract 16998: Gender and Age Specific Baseline Predictors of MACE in PEACE Trial Identified by Machine Learning

Circulation2020-11-17

Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease.

2014-04-0975 citations

Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease.

2013-02-13234 citations